Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
Santini A, Tassinari E, Poeta E, Loi M, Ciani E, Trazzi S, Piccarducci R, Daniele S, Martini C, Pagliarani B, Tarozzi A, Bersani M, Spyrakis F, Danková D, Olsen CA, Soldati R, Tumiatti V, Montanari S, De Simone A, Milelli A. Santini A, et al. Among authors: tassinari e. ACS Chem Neurosci. 2024 May 15. doi: 10.1021/acschemneuro.4c00061. Online ahead of print. ACS Chem Neurosci. 2024. PMID: 38747979
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience.
Mollica V, Marchetti A, Fraccascia N, Nanni C, Tabacchi E, Malizia C, Argalia G, Rosellini M, Tassinari E, Paccapelo A, Fanti S, Massari F. Mollica V, et al. Among authors: tassinari e. ESMO Open. 2024 May;9(5):103448. doi: 10.1016/j.esmoop.2024.103448. Epub 2024 May 7. ESMO Open. 2024. PMID: 38718704 Free PMC article. Clinical Trial.
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, Biase D, Massari F. Mollica V, et al. Among authors: tassinari e. Pathol Res Pract. 2024 Jan;253:155008. doi: 10.1016/j.prp.2023.155008. Epub 2023 Dec 8. Pathol Res Pract. 2024. PMID: 38103361
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.
Rosellini M, Tassinari E, Marchetti A, Mollica V, Massari F. Rosellini M, et al. Among authors: tassinari e. Eur Urol. 2024 Jan;85(1):97-98. doi: 10.1016/j.eururo.2023.09.011. Epub 2023 Sep 28. Eur Urol. 2024. PMID: 37777426 No abstract available.
59 results